Numerous components of 42 different wines have been analysed using state-of-the-art equipment for the first time. The data generated will provide an extremely accurate basis for definitively characterising different wine varieties, as well as an innovative approach for routine wine analysis ... more
Therapeutic Antibodies Show Variations
Subtle Differences: Therapeutic Antibodies Vary Depending on Production System
Differences in production methods for therapeutic antibodies can lead to variations in their structure, depending on the recombinant procedure selected. The distinctions, which are based on a number of glycosylations, even impact antibodies’ stability. This was the result of a high-precision comparison of the structural properties of antibody isotopes that were manufactured in cell cultures or plants. Equipment BOKU (EQ BOKU) based at the University of Natural Resources and Life Sciences, Vienna (BOKU) employed state-of-the-art mass spectrometers to pinpoint minute differences in the glycosylation of immunoglobulins.
Antibodies are one of the most precise forms of medicine and are increasingly being used to combat cancer and other conditions. They are frequently produced recombinantly, with a range of different manufacturing processes in use. Each process creates an identical protein scaffold in the antibody, but there are differences in what is known as glycosylation, or modification by adding specific carbohydrates. Previously, little was known about the way in which these differences come about and the form they take. Identifying these subtle, but potentially medically significant distinctions requires extremely complex analysis, which is only possible using the latest mass spectrometry procedures. A BOKU team had access to such equipment at the university’s EQ BOKU facility and unearthed some surprising results.
Getting to the heart of the matter
The team headed by Prof. Richard Strasser is the first to identify precise differences in the glycosylation patterns of immunoglobulin A, which had been produced either in human cell cultures (HEK293) or plant systems (Nicotiana benthamiana). Prof. Strasser, a member of the Department of Applied Genetics and Cell Biology, commented: “Even we were surprised by how big the differences were. There were sharp contrasts between the two systems in terms of the structure of the carbohydrates used for glycosylation and their position on the proteins.”
With the help of ultra-modern techniques called capillary reversed-phase chromatography and electrospray mass spectrometry provided by EQ, the team managed to analyse glycosylation in each system down to the finest detail. They found that the immunoglobulin A produced in the HEK293 cell culture had many more and also more complex N-glycans – a group of carbohydrates that bond with particular nitrogen atoms – than that produced in mammalian cell cultures. The immunoglobulin A manufactured in plants also had a significantly narrower range of structures. This was primarily due to the fact that plants have none of the metabolic pathways required for mammalian glycosylation. “But we also saw glycosylations in the antibodies manufactured in plants which can only occur in plants,” Prof. Strasser added.
Although the glycosylations in the antibodies produced in N. benthamiana were purely plant-specific, the antibodies displayed the same bonding properties for antigens as those manufactured using human cells. This suggests that as far as therapeutic applications are concerned, the choice of production system makes no difference. However, further analysis by Prof. Strasser’s team revealed that the stability of immunoglobulin A varies depending on the production method – a factor which could have a decisive effect on its use in treatment. The analysis involved testing the antibodies’ thermal stability, which turned out to be lower in immunoglobulin A produced in plants. “We need to carry out further tests to discover how significant this is for the application of these antibodies in treatment,” Prof. Strasser explained.
Thanks to genes acquired from bacteria, a fungus can degrade an environmentally harmful hydrocarbon - and comes under considerable stress in the process. These remarkable research findings, which were published recently, were obtained by a group from the University of Natural Resources and ... more
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies t ... more
- 1A new, highly sensitive chemical sensor uses protein nanowires
- 2New COVID-19 test quickly and accurately detects viral RNA
- 3Diagnostic biosensor quickly detects SARS-CoV-2 from nasopharyngeal swabs
- 4Researcher Develops One Minute Coronavirus Test
- 5How cells recognize uninvited guests
- 6Beta cells from stem cells: Potential for cell replacement therapy
- 7A new biosensor for the COVID-19 virus
- 8New Form of Microscopy Developed
- 9The Higgs boson and superconductivity
- 10Herpes virus decoded using new methods
- Breaking down stubborn cellulose in time lapse
- Single-cell RNA seq method developed to accurately quantify cell-specific drug effects in pancreatic islets
- First SARS-CoV-2 genomes in Austria openly available
- University of Innsbruck develops novel corona test method
- Researchers observe ultrafast processes of single molecules in liquid helium for the first time